Investors might want to bet on Sendas Distribuidora S.A. Sponsored ADR (ASAIY) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus E ...

Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 13.7% over the past four weeks, with analysts projecting a mean price target of $316.82, indicating a potential upside of 25.3% from the current price of $252.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $34.23, suggesting variability in analyst predictions. The lowest estimate is $260.00 (2.8% increase), while the highest is $355.00 (40.4% increase) [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding WST's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. Four estimates have increased over the last 30 days, with no negative revisions, leading to a 7.8% increase in the Zacks Consensus Estimate [11][12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead. Empirical research suggests that price targets rarely indicate actual stock price movements, and analysts may set overly optimistic targets due to business incentives [7][8][10]

Core Viewpoint - Genius Sports Limited (GENI) has shown a 0.7% increase in share price over the past four weeks, closing at $10.17, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $12.82, representing a 26.1% upside [1] Price Targets - The average of 17 short-term price targets ranges from a low of $11.00 to a high of $15.00, with a standard deviation of $1.13, indicating variability among analysts [2] - The lowest estimate suggests an 8.2% increase from the current price, while the highest estimate indicates a 47.5% upside [2] Analyst Sentiment - Analysts have shown increasing optimism regarding GENI's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with one estimate increasing and no negative revisions [12] Zacks Rank - GENI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains for GENI, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Nomad Foods (NOMD) shows potential for significant upside, with a mean price target of $24 indicating a 37.2% increase from the current price of $17.49 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $2.37, suggesting a range of estimates from $20.00 (14.4% increase) to $27.00 (54.4% increase) [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts exhibit growing optimism about NOMD's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates with near-term stock price movements [11] - Over the last 30 days, one estimate has increased, leading to a 1.7% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - NOMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Group 1 - HNI closed at $51.83, with a 1.3% gain over the past four weeks, and analysts set a mean price target of $68.75, indicating a 32.7% upside potential [1] - The average price targets range from a low of $60.00 to a high of $80.00, with a standard deviation of $8.54, suggesting a 15.8% to 54.4% upside based on the lowest and highest estimates respectively [2] - Analysts show strong agreement on HNI's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for HNI's current year earnings has increased by 1.4% over the past month, with two estimates revised higher and no negative revisions [12] - HNI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide for potential upside [14]

Group 1 - Montrose Environmental (MEG) shares have increased by 2.1% over the past four weeks, closing at $22.39, with a mean price target of $29.4 indicating a potential upside of 31.3% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $4.83, where the lowest estimate is $24.00 (7.2% increase) and the highest is $35.00 (56.3% increase) [2] - Analysts show a consensus that MEG will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for MEG has increased by 4.7% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - MEG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting the extent of MEG's gains, they can provide a directional guide for price movement [14]

Group 1 - Tango Therapeutics, Inc. (TNGX) shares have increased by 18.7% over the past four weeks, closing at $6.46, with a mean price target of $10.43 indicating a potential upside of 61.5% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $2.23, where the lowest estimate is $8.00 (23.8% increase) and the highest is $13.00 (101.2% increase) [2] - Analysts show strong agreement on TNGX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for TNGX has increased by 1% due to one upward revision in earnings estimates over the last 30 days, with no negative revisions [12] - TNGX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Group 1 - CRISPR Therapeutics AG (CRSP) has an average brokerage recommendation (ABR) of 1.88, indicating a consensus between Strong Buy and Buy based on 27 brokerage firms' recommendations [2][5] - Out of the 27 recommendations, 15 are classified as Strong Buy, accounting for 55.6%, while one is classified as Buy, accounting for 3.7% [2] - Despite the positive ABR, reliance solely on brokerage recommendations may not be advisable, as studies suggest they often fail to guide investors effectively towards stocks with high price appreciation potential [5][10] Group 2 - Brokerage analysts tend to exhibit a strong positive bias in their ratings due to vested interests, often resulting in a disproportionate number of Strong Buy recommendations compared to Strong Sell [6][10] - The Zacks Rank, a proprietary stock rating tool, is presented in whole numbers and is based on earnings estimate revisions, which have shown a strong correlation with near-term stock price movements [8][11] - The Zacks Consensus Estimate for CRISPR Therapeutics has declined by 1.4% over the past month to -$5.61, indicating growing pessimism among analysts regarding the company's earnings prospects [14][15] Group 3 - The recent change in the consensus estimate, along with other earnings-related factors, has led to a Zacks Rank of 4 (Sell) for CRISPR Therapeutics, suggesting caution despite the favorable ABR [15] - The ABR may not always reflect the most current information, while the Zacks Rank is updated more frequently to reflect changes in earnings estimates [13]

Check price target & stock forecast for Archrock Inc. here>>> When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Archrock Inc. (AROC) before we discuss the reliability of brokerage recommendations and how to use them to your advan ...

Core Viewpoint - CNH Industrial (CNH) is expected to report a significant decline in quarterly earnings and revenues, with earnings per share projected at $0.16, down 57.9% year over year, and revenues forecasted at $4.53 billion, a decrease of 17.5% compared to the previous year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 3.3%, indicating a reassessment by analysts of their initial projections [1][2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [2]. Revenue Projections - Analysts estimate 'Revenues- Net Sales' to be $3.87 billion, reflecting a year-over-year decline of 19.4% [4]. - 'Revenues- Total Industrial Activities- Agriculture' is projected at $2.97 billion, indicating a decrease of 24% from the prior year [4]. - 'Revenues- Total Industrial Activities- Construction' is expected to reach $783.84 million, down 11.9% year over year [5]. - 'Revenues- Finance, interest and other income' is forecasted at $661.32 million, a decline of 3.5% from the previous year [5]. Segment-Specific Sales Estimates - 'Agriculture Sales- North America' is anticipated to be $1.24 billion, down 28.8% year over year [5]. - 'Agriculture Sales- Europe, Middle East and Africa' is projected at $997.86 million, reflecting a decrease of 16.2% [6]. - 'Agriculture Sales- South America' is expected to reach $489.02 million, indicating a decline of 12.5% [6]. - 'Construction Sales- Asia Pacific' is forecasted at $55.77 million, down 7.1% from the prior year [6]. - 'Construction Sales- North America' is estimated to be $416.17 million, reflecting a decrease of 17.3% [7]. - 'Construction Sales- Europe, Middle East and Africa' is projected at $166.04 million, down 4.6% year over year [7]. - 'Construction Sales- South America' is expected to reach $146.14 million, indicating a decline of 4.5% [8]. - 'Agriculture Sales- Asia Pacific' is projected at $354.72 million, down 16.3% from the previous year [8]. Stock Performance - CNH shares have experienced a decline of 4.1% over the past month, contrasting with a 3.4% increase in the Zacks S&P 500 composite [8].